The Estrogen Receptor Beta pipeline drugs market research report outlays comprehensive information on the Estrogen Receptor Beta targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Estrogen Receptor Beta pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Central Nervous System, Women’s Health, and Metabolic Disorders which include the indications Breast Cancer, Prostate Cancer, Multiple Sclerosis, Depression, Menopausal Disorders, Endometriosis, Obesity, and Niemann-Pick Disease Type C. It also reviews key players involved in Estrogen Receptor Beta targeted therapeutics development with respective active and dormant or discontinued products.
The Estrogen Receptor Beta pipeline targets constitutes close to 18 molecules. Out of which, approximately 12 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical, and Discovery stages are 1, 2, 2, 4, and 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical, and Discovery comprises 1, 2, and 3 molecule.
Estrogen Receptor Beta overview
Estrogen receptor beta (ERB) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR2. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription.
For a complete picture of Estrogen Receptor Beta’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
